Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials—Phase 2/3 AD and Phase 3 PD. Both studies yielded promising results, reinforcing ...

was the first FcRn blocker to be approved by the FDA, getting the go-ahead in December 2021 for generalised myasthenia gravis (gMG). Vyvgart Hytrulo was cleared for gMG in the US a year ago ...

Welcome to Maravai LifeSciences fourth quarter 2024 results earnings call. At this time, all participants are in a ...